Company: Johnson & Johnson (Janssen)
Posted by JanssenInsider99 · May 24, 2026
Tags: strategy, rumors, culture
Hearing more and more chatter that JD is looking to spin off even more of the MedTech/Consumer legacy biz to make J&J a 'pure-play' pharma powerhouse.
First it was Kenvue, then Depuy Synthes, and now the rumor mill says Ethicon might be next on the block.
As a Janssen rep, it's great to be the 'favorite child' for once, but the constant shuffling is making everyone nervous.
Are we looking at a total rebrand or just more territory 'optimization' to fit the new model? Anyone on the MedTech side hearing anything concrete?.
0 upvotes · 0 comments